Access cutting-edge crohn's disease treatment through this clinical trial at a research site in Atlanta. Study-provided care at no cost to qualified participants.
Access crohn's disease specialists in Atlanta at no cost
This study follows strict safety protocols and ethical guidelines
All study-related crohn's disease treatment provided free
Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease. Study periods for the intervention-specific appendix (ISA) will be as follows: * A 12-week induction period * A maintenance period from Week 12 to Week 52, and * A safety follow-up period
Sponsor: Eli Lilly and Company
Check if you qualify for this crohn's disease clinical trial in Atlanta, GA
If you're searching for crohn's disease treatment options in Atlanta, GA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Atlanta research site is actively enrolling participants for this clinical trial. You'll receive care from experienced crohn's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.